Last reviewed · How we verify
Semprex-D (ACRIVASTINE)
At a glance
| Generic name | ACRIVASTINE |
|---|---|
| Sponsor | Auxilium Pharms Inc |
| Drug class | Histamine-1 Receptor Antagonist |
| Target | Histamine H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1994 |
Approved indications
- Allergic conjunctivitis
- Allergic rhinitis
- Common cold
- Nasal congestion
- Nasal discharge
- Seasonal allergic rhinitis
- Sneezing
- Vasomotor rhinitis
Common side effects
- Somnolence
- Headache
- Nausea
- Dizziness
- Palpitations
- Tachycardia
- Tremor
- Insomnia
- Nervousness
Serious adverse events
- Anaphylaxis
- Angioedema
- Bronchospasm
- Erythema multiforme
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Semprex-D CI brief — competitive landscape report
- Semprex-D updates RSS · CI watch RSS
- Auxilium Pharms Inc portfolio CI